ArticleJournal of diabetes science and technology2025
One Size Does Not Fit All: The Need for Sex-Specific Precision Medicine in Diabetes Technology.
Article in Journal of diabetes science and technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Modeling ovarian hormone effects on glucose-insulin control in type 1 diabetes.Bioengineering & translational medicine · 2026Review
- Technology in Diabetes: A Year in Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Transformations in Diabetes Care: Lessons From Commons-Based, Peer-Produced Citizen Science.Sociology of health & illness · 2026Article
- Challenges in glycaemic control among women with type 1 diabetes and the role of MiniMed 780G system: A narrative review.Diabetes, obesity & metabolism · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Incorporating sex-specific factors in diabetes research and treatment is essential for advancing precision medicine. There are critical gaps in understanding and applying sex-related differences. Female-specific diabetes pathophysiology manifests in three major areas: life cycle phases (including puberty, pregnancy, and menopause), lifestyle factors (such as responses to nutrition and physical activity), and insulin pharmacology. These elements significantly affect insulin sensitivity and glycemic control in women, yet are frequently underrepresented or ignored in both research and clinical practice. Greater research and clinical focus across these domains is needed to better understand and address sex-based differences in diabetes. Identifying and filling evidence gaps will support more systematic and effective care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.